Región Metropolitana de Santiago
Este organismo compró $35.329.096.472 en 11.633 órdenes de compra , sobre todo en Medicamentos y productos farmacéuticos / Medicamentos anti infecciosos / Medicamentos antivirales y le compró principalmente a Sur Medical SpA.
238 meses con data · color por monto (sqrt scale)
| Año | Ene | Feb | Mar | Abr | May | Jun | Jul | Ago | Sep | Oct | Nov | Dic | Total año |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
| $1367,1 M |
| 2025 | $2402,7 M |
| 2024 | $2107,2 M |
| 2023 | $2816,8 M |
| 2022 | $1338 M |
| 2021 | $1018,6 M |
| 2020 | $888,8 M |
| 2019 | $901,2 M |
| 2018 | $1471,2 M |
| 2017 | $786,1 M |
| 2016 | $14,2 mil M |
| 2015 | $919,8 M |
| 2014 | $428,8 M |
| 2013 | $340,8 M |
| 2012 | $359,5 M |
| 2011 | $701,4 M |
| 2010 | $913,7 M |
| 2009 | $590,7 M |
| 2008 | $571,8 M |
| 2007 | $1180,7 M |
| 2006 | $34,7 M |
238 períodos con data
Fuente: Agregaciones mensuales sobre OCs ingeridas
10 contrapartes
Fuente: Tabla top_contrapartes_comprador
| Código | Fecha | Proveedor | Estado | Monto |
|---|---|---|---|---|
| 2980-932-AG25 | 19-12-2025 | Productos Farmoquimicos Roche Limitada | Recepcion Conforme | $5.617.485 |
| 2980-934-AG25 | 19-12-2025 | Astrazeneca S.A. | Recepcion Conforme | $6.129.404 |
| 2980-966-AG25 | 19-12-2025 | Laboratorio Biotoscana Farma SpA | Recepcion Conforme | $3.718.155 |
| 2980-965-AG25 | 19-12-2025 | Johnson y Johnson de Chile S.A. | Recepcion Conforme | $6.669.902 |
| 2980-967-AG25 | 19-12-2025 | Synthon Chile Limitada | Recepcion Conforme | $376.040 |
| 2980-969-AG25 | 19-12-2025 | Glaxosmithkline Chile Farmaceutica Limitada | Recepcion Conforme | $4.895.327 |
| 2980-960-AG25 | 18-12-2025 | Novartis Chile S.A. | Recepcion Conforme | $6.396.431 |
| 2980-961-AG25 | 18-12-2025 | Glaxosmithkline Chile Farmaceutica Limitada | Recepcion Conforme | $738.347 |
| 2980-927-AG25 | 18-12-2025 | Novartis Chile S.A. | Recepcion Conforme | $4.285.428 |
| 2980-928-AG25 | 18-12-2025 | Pfizer Chile S.A. | Recepcion Conforme | $3.519.235 |
| 2980-940-AG25 | 18-12-2025 | Glaxosmithkline Chile Farmaceutica Limitada | Recepcion Conforme | $2.335.637 |
| 2980-938-AG25 | 16-12-2025 | Astrazeneca S.A. | Recepcion Conforme | $5.678.261 |
| 2980-939-AG25 | 16-12-2025 | Synthon Chile Limitada | Recepcion Conforme | $807.177 |
| 2980-941-AG25 | 16-12-2025 | Glaxosmithkline Chile Farmaceutica Limitada | Recepcion Conforme | $821.029 |
| 2980-942-AG25 | 16-12-2025 | Bayer S.A. | Recepcion Conforme | $6.735.909 |
| 2980-943-AG25 | 16-12-2025 | Novofarma Service S.A. | Recepcion Conforme | $4.760.095 |
| 2980-959-AG25 | 16-12-2025 | Novartis Chile S.A. | Recepcion Conforme | $5.395.291 |
| 2980-962-AG25 | 16-12-2025 | Gador Limitada | Recepcion Conforme | $2.040.850 |
| 2980-963-AG25 | 16-12-2025 | Glaxosmithkline Chile Farmaceutica Limitada | Recepcion Conforme | $352.240 |
| 2980-968-AG25 | 16-12-2025 | Abbvie Productos Farmaceuticos Limitada | Recepcion Conforme | $2.685.916 |
| 2980-935-AG25 | 16-12-2025 | Novartis Chile S.A. | Recepcion Conforme | $5.895.474 |
| 2980-936-AG25 | 16-12-2025 | Becrux Labs SpA | Recepcion Conforme | $1.870.680 |
| 2980-937-AG25 | 16-12-2025 | Distribuidora Qualimed Limitada | Recepcion Conforme | $1.414.910 |
| 2980-920-AG25 | 10-12-2025 | Laboratorios Andromaco S.A. | Recepcion Conforme | $3.065.440 |
| 2980-923-AG25 | 10-12-2025 | Astrazeneca S.A. | Recepcion Conforme | $4.955.084 |
| 2980-924-AG25 | 10-12-2025 | Clinical Market S.A. | Recepcion Conforme | $4.680.389 |
| 2980-926-AG25 | 10-12-2025 | Novofarma Service S.A. | Recepcion Conforme | $1.020.889 |
| 2980-933-AG25 | 10-12-2025 | Novartis Chile S.A. | Recepcion Conforme | $5.895.474 |
| 2980-913-AG25 | 25-11-2025 | Unión del Sur Producciones Limitada | Recepcion Conforme | $1.899.999 |
| 2980-919-AG25 | 25-11-2025 | Inversiones Sb S.A. | Recepcion Conforme | $696.150 |
